These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11856251)

  • 41. In-vitro activity of grepafloxacin, a new fluoroquinolone, against mycoplasmas.
    Bébéar CM; Renaudin H; Schaeverbeke T; Leblanc F; Bébéar C
    J Antimicrob Chemother; 1999 May; 43(5):711-4. PubMed ID: 10382895
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Susceptibility of Legionella species to five antibiotics and development of resistance by exposure to erythromycin, ciprofloxacin, and rifampicin.
    Nielsen K; Bangsborg JM; Høiby N
    Diagn Microbiol Infect Dis; 2000 Jan; 36(1):43-8. PubMed ID: 10744366
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Respiratory pathogens: assessing resistance patterns in Europe and the potential role of grepafloxacin as treatment of patients with infections caused by these organisms.
    Felmingham D
    J Antimicrob Chemother; 2000 Mar; 45():1-8. PubMed ID: 10719006
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Practical problems raised by antibiotic minimal inhibitory concentration determination in Legionella species (author's transl)].
    Bornstein N; Roudier C; Fleurette J
    Pathol Biol (Paris); 1982 Jun; 30(6):421-5. PubMed ID: 6810285
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The in-vitro activity of moxifloxacin against Legionella species and the effects of medium on susceptibility test results.
    Ruckdeschel G; Dalhoff A
    J Antimicrob Chemother; 1999 May; 43 Suppl B():25-9. PubMed ID: 10382872
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antibiotic Susceptibility of Environmental
    Cocuzza CE; Martinelli M; Perdoni F; Giubbi C; Vinetti MEA; Calaresu E; Frugoni S; Scaturro M; Ricci ML; Musumeci R
    Int J Environ Res Public Health; 2021 Sep; 18(17):. PubMed ID: 34501942
    [No Abstract]   [Full Text] [Related]  

  • 47. Evaluation of a human monocytic cell line THP-1 model for assay of the intracellular activities of antimicrobial agents against Legionella pneumophila.
    Takemura H; Yamamoto H; Kunishima H; Ikejima H; Hara T; Kanemitsu K; Terakubo S; Shoji Y; Kaku M; Shimada J
    J Antimicrob Chemother; 2000 Oct; 46(4):589-94. PubMed ID: 11020257
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of quinolones and other antimicrobial agents on cell-associated Legionella pneumophila.
    Havlichek D; Saravolatz L; Pohlod D
    Antimicrob Agents Chemother; 1987 Oct; 31(10):1529-34. PubMed ID: 3435101
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bactericidal activity of moxifloxacin compared to grepafloxacin and clarithromycin against Streptococcus pneumoniae and Streptococcus pyogenes investigated using an in vitro pharmacodynamic model.
    Esposito S; Noviello S; Ianniello F
    J Chemother; 2000 Dec; 12(6):475-81. PubMed ID: 11154028
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effects of single and combined antibiotics on the growth of Legionella pneumophila using time-kill studies.
    Barker JE; Farrell ID
    J Antimicrob Chemother; 1990 Jul; 26(1):45-53. PubMed ID: 2211446
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Susceptibility of Legionella species to antimicrobial agents.
    Chen SC; Paul ML; Gilbert GL
    Pathology; 1993 Apr; 25(2):180-3. PubMed ID: 8367199
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Minimum inhibitory concentration (MIC) distribution among wild-type strains of Legionella pneumophila identifies a subpopulation with reduced susceptibility to macrolides owing to efflux pump genes.
    Vandewalle-Capo M; Massip C; Descours G; Charavit J; Chastang J; Billy PA; Boisset S; Lina G; Gilbert C; Maurin M; Jarraud S; Ginevra C
    Int J Antimicrob Agents; 2017 Nov; 50(5):684-689. PubMed ID: 28782709
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative in vitro activity of ciprofloxacin and other unrelated antimicrobials against bacterial respiratory tract pathogens.
    Felmingham D; Robbins MJ; Baskerville AJ; Sanghrajka MD; Ridgway GL; Grüneberg RN
    Drugs Exp Clin Res; 1989; 15(2):59-62. PubMed ID: 2737080
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro activity of ABT-773 against Legionella pneumophila, its pharmacokinetics in guinea pigs, and its use to treat guinea pigs with L. pneumophila pneumonia.
    Edelstein PH; Higa F; Edelstein MA
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2685-90. PubMed ID: 11557455
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacodynamic studies of moxifloxacin and erythromycin against intracellular Legionella pneumophila in an in vitro kinetic model.
    Tano E; Cars O; Löwdin E
    J Antimicrob Chemother; 2005 Jul; 56(1):240-2. PubMed ID: 15919770
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro activity of rufloxacin against Listeria monocytogenes, Legionella pneumophila, and Chlamydia trachomatis.
    Furneri PM; Bazzano M; Campo L; Cesana M; Tempera G
    Chemotherapy; 1994; 40(2):104-8. PubMed ID: 8131632
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro and in vivo activity of olamufloxacin (HSR-903) against Legionella spp.
    Higa F; Arakaki N; Tateyama M; Koide M; Shinzato T; Kawakami K; Saito A
    J Antimicrob Chemother; 2003 Dec; 52(6):920-4. PubMed ID: 14613952
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Postantibiotic effect of various antibiotics on Legionella pneumophila strains isolated from water systems.
    Birteksöz-Tan AS; Zeybek Z
    Folia Microbiol (Praha); 2012 Nov; 57(6):495-9. PubMed ID: 22627604
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Wild-type MIC distribution and epidemiological cut-off values in clinical Legionella pneumophila serogroup 1 isolates.
    Bruin JP; Ijzerman EP; den Boer JW; Mouton JW; Diederen BM
    Diagn Microbiol Infect Dis; 2012 Jan; 72(1):103-8. PubMed ID: 22100012
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bactericidal activity and postantibiotic effect of clarithromycin and 14-hydroxyclarithromycin, alone and in combination, against Legionella pneumophila.
    Martin SJ; Pendland SL
    J Antimicrob Chemother; 1998 Jun; 41(6):643-8. PubMed ID: 9687103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.